Evidence map›Paper›PMID 29476776›Full record

Trial reportThe Journal of investigative dermatology2018

β-Adrenergic Receptor Trafficking, Degradation, and Cell Surface Expression Are Altered in Dermal Fibroblasts from Hypertrophic Scars.

Amina El Ayadi, Anesh Prasai, Ye Wang, David N Herndon, Celeste C Finnerty

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amina El AyadiDepartment of Surgery, University of Texas Medical Branch, Galveston, Texas, USA; Shriners Hospitals for Children-Galveston, Galveston, Texas, USA. Electronic address: amelayad@utmb.edu.
Anesh PrasaiDepartment of Surgery, University of Texas Medical Branch, Galveston, Texas, USA; Shriners Hospitals for Children-Galveston, Galveston, Texas, USA.
Ye WangDepartment of Surgery, University of Texas Medical Branch, Galveston, Texas, USA; Shriners Hospitals for Children-Galveston, Galveston, Texas, USA.
David N HerndonDepartment of Surgery, University of Texas Medical Branch, Galveston, Texas, USA; Shriners Hospitals for Children-Galveston, Galveston, Texas, USA.
Celeste C FinnertyDepartment of Surgery, University of Texas Medical Branch, Galveston, Texas, USA; Shriners Hospitals for Children-Galveston, Galveston, Texas, USA; Institute for Translational Sciences and Sealy Center for Molecular Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
Shriners Hospitals for Children - Galveston · US

Funding

UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
Project 9: The role of androgen/corticosteroid in fat, muscle and glucose metabolism of burn victimsP50GM060338 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI HERNDON, DAVID N. · 2000 to 2017
$24.2M
UTMB Clinical and Translational Science AwardUL1TR000071 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$14.4M
MODULATION OF THE POSTBURN HYPERMETABOLIC RESPONSER01GM056687 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI HERNDON, DAVID N. · 1998 to 2017
$9.0M
Effects of Chronic Catecholamine Exposure on Post-burn ScarringR01GM112936 · NIGMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI FINNERTY, CELESTE CAMPBELL · 2015 to 2019
$1.8M
NCATS NIH HHS UL1 TR000071NCATS NIH HHS UL1 TR001439NIGMS NIH HHS P50 GM060338NIGMS NIH HHS R01 GM056687NIGMS NIH HHS R01 GM112936
6 · The paper itself

Abstract

Burn trauma elevates catecholamines for up to 2 years and causes hypertrophic scarring. Propranolol, a nonspecific β1-, β2-adrenergic receptor (AR) inverse agonist, counters the hypermetabolic response to elevated catecholamines and may decrease hypertrophic scarring by an unknown mechanism. We investigated the effect of burn injury on β1-, β2-, and β3-AR expression, trafficking, and degradation in human dermal fibroblasts from hypertrophic scar [HSF], non-scar fibroblasts, and normal fibroblasts. We also investigated the modulation of these events by propranolol. Catecholamine-stimulated cAMP production was lower in HSFs and non-scar fibroblasts than in normal fibroblasts. β1- and β2-AR cell surface expression was lowest in HSFs, but propranolol increased cell surface expression of these receptors. Basal β2-AR ubiquitination was higher in HSFs than non-scar or normal fibroblasts, suggesting accelerated receptor degradation. β-AR degradation was mainly driven by lysosomal-specific polyubiquitination at Lys-63 in normal fibroblasts and HSFs, which was abrogated by propranolol. Propranolol also targeted β-AR to the proteasome in HSFs. Confocal imaging showed a lack of β2-AR-GFP trafficking to lysosomal compartments in catecholamine-stimulated HSFs. These data suggest that burn trauma alters the expression, trafficking, and degradation of β-ARs in dermal fibroblasts, which may then affect fibroblast responses to propranolol.

Indexed as

AdolescentAdrenergic beta-AgonistsBiopsyBurnsCell MembraneCells, CulturedChildChild, PreschoolCicatrix, HypertrophicFibroblastsHumansInfantLysosomesPropranololProteasome Endopeptidase ComplexProteolysisAdrenergic beta-AgonistsPropranololProteasome Endopeptidase ComplexReceptors, Adrenergic, beta

Identifiers

PMID29476776
PMCPMC6021177
OpenAlexW2788810927

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.